Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Finished Goods (2020 - 2025)

Historic Finished Goods for Fortress Biotech (FBIO) over the last 6 years, with Q1 2025 value amounting to $10.0 million.

  • Fortress Biotech's Finished Goods rose 7094.63% to $10.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $10.0 million, marking a year-over-year increase of 7094.63%. This contributed to the annual value of $11.4 million for FY2024, which is 12821.34% up from last year.
  • Fortress Biotech's Finished Goods amounted to $10.0 million in Q1 2025, which was up 7094.63% from $11.4 million recorded in Q4 2024.
  • In the past 5 years, Fortress Biotech's Finished Goods registered a high of $11.4 million during Q4 2024, and its lowest value of $4.3 million during Q4 2021.
  • Over the past 5 years, Fortress Biotech's median Finished Goods value was $7.1 million (recorded in 2023), while the average stood at $7.3 million.
  • In the last 5 years, Fortress Biotech's Finished Goods skyrocketed by 20555.56% in 2021 and then crashed by 3556.01% in 2023.
  • Fortress Biotech's Finished Goods (Quarter) stood at $4.3 million in 2021, then soared by 80.4% to $7.7 million in 2022, then crashed by 35.56% to $5.0 million in 2023, then skyrocketed by 128.21% to $11.4 million in 2024, then decreased by 11.91% to $10.0 million in 2025.
  • Its last three reported values are $10.0 million in Q1 2025, $11.4 million for Q4 2024, and $8.7 million during Q3 2024.